Evidence map›Paper›PMID 31853144›Full record

ArticleThe Canadian journal of hospital pharmacy

Clinical Interventions to Prevent Tumour Lysis Syndrome in Hematologic Malignancy: A Multisite Retrospective Chart Review.

Sarah McKenna, Alexandra Cheung, Amanda Wolfe, Brenda L Coleman, Michael E Detsky, Laveena Munshi, Dawn Maze, Lisa Burry

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in The Canadian journal of hospital pharmacy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sarah McKennaPharmD, ACPR, is with the Department of Pharmacy, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario.
Alexandra Cheung, BScPhm, PharmD, is with the Department of Pharmacy, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario.
Amanda Wolfe(formerly Amanda Jacques), BScPharm, ACPR, was, at the time this study was conducted, with the Department of Pharmacy, Princess Margaret Cancer Centre, University Health Network, and the Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario. She is now with the Department of Pharmacy, Bruyère Continuing Care, Ottawa, Ontario.
Brenda L ColemanPhD, is with Infectious Disease Research, Mount Sinai Hospital, Sinai Health System, and the Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario.
Michael E DetskyMD, MSHP, FRCPC, is with the Interdepartmental Division of Critical Care, University Health Network/Sinai Health System, and the Interdepartmental Division of Critical Care and Faculty of Medicine, University of Toronto, Toronto, Ontario.
Laveena MunshiMD, MSc, FRCPC, is with the Interdepartmental Division of Critical Care, University Health Network/Sinai Health System, Toronto, Ontario.
Dawn MazeMD, MSc, FRCPC, is with the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, and the Faculty of Medicine, University of Toronto, Toronto, Ontario.
Lisa BurryPharmD, is with the Department of Pharmacy, Mount Sinai Hospital, Sinai Health System, and the Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.
Mount Sinai Health System · USUniversity Health Network · CAMount Sinai Hospital · CASinai Health System · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumour lysis syndrome (TLS) occurs when lysis of malignant cells causes electrolyte disturbances and potentially organ dysfunction. Guidelines recommending preventive therapy according to TLS risk are based on low-quality evidence.

objectivesThe primary objective was to characterize utilization of TLS preventive strategies through comprehensive description of current practice. Secondary objectives were to determine TLS incidence, to compare use of preventive strategies among intermediate- and high-risk patients, and to describe TLS treatment strategies.

methodsThis retrospective chart review examined data for patients with newly diagnosed hematologic malignancy who were admitted to an oncology centre and/or affiliated intensive care unit between October 2015 and September 2016 in Toronto, Ontario, Canada.

resultsFifty-eight patients (29 at intermediate risk, 29 at high risk) were eligible for inclusion. Use of preventive allopurinol, IV bicarbonate, and furosemide was similar between groups. Rasburicase was more frequently used for high-risk patients (3% [1/29] of intermediate-risk patients versus 36% [9/25] of high-risk patients;

conclusionsIn this retrospective chart review, rasburicase was more commonly used for high-risk patients, whereas the use of other agents was similar between risk groups. This pattern of use is inconsistent with guidelines, which recommend that all high-risk patients receive rasburicase. There was no difference in TLS incidence between patients who did and did not receive preventive rasburicase or IV bicarbonate. Further prospective studies are needed to inform management of patients with malignancies who are at intermediate or high risk of TLS.

Indexed as

allopurinolbicarbonaterasburicasetumour lysis syndrome

Identifiers

PMID31853144
PMCPMC6910844
OpenAlexW2996658084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.